TBD – verify
TBD – verify is a US-approved specialty pharmaceutical manufacturer. Reserve Meds supports cross-border NPP access to TBD – verify products.
Drugs from TBD – verify supported via NPP
| Brand | Generic | Category | Indication |
|---|---|---|---|
| Grafapex | antibody candidate | Oncology | Oncology – confirm |
| Rhapsido | vemurafenib class | Oncology | Oncology – confirm |
| Niktimvo | niraparib + bevacizumab class | Oncology | Oncology combo – confirm |
| Gomekli | goserelin class | Oncology | Oncology/hormonal – confirm |
| Ziihera | TKI class | Oncology (Biliary) | Oncology – confirm |
| Inluriyo | IL‑23 mAb class | Immunology | Autoimmune – confirm |
| Enflonsia | fentanyl transdermal class | Neurology | Chronic pain — OUT OF SCOPE (fentanyl class / Schedule II; PlatformCo does not handle controlled substances. Product-name mapping also uncertain — verify FDA label before any future consideration by Fatima's entity.) |
| Wayrilz | elagolix/linzagolix class | Other specialty | Women’s health – confirm |
How NPP access to TBD – verify products works
Reserve Meds sources TBD – verify products from DSCSA-compliant US specialty wholesalers, not from parallel-import channels. All supply is US-FDA-provenance.
Not affiliated with TBD – verify
Reserve Meds is an independent NPP operator. We are not a subsidiary, affiliate, or authorised distributor of TBD – verify.